Female Pattern Baldness
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Fitzpatrick CompanyON - Waterloo
1 program1550nm non-ablative fractional laserN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
EMSOMA102
Energenesis BiomedicalENERGI-F701
Fitzpatrick Company1550nm non-ablative fractional laser
Clinical Trials (3)
Total enrollment: 581 patients across 3 trials
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
Start: Jan 2025Est. completion: Jan 2027504 patients
Phase 3Not Yet Recruiting
ENERGI-F701 for Female Hair Loss Treatment
Start: May 2018Est. completion: Dec 201967 patients
Phase 2Completed
1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss
Start: May 2025Est. completion: Dec 202510 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.